Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)
Description
The subject of this publication is the conclusion of agreements under § 130a para. 8 SGB V for finished medicinal products with various active substances or active substance combinations within the framework of a so-called "Open-House Model". Admission or contract conclusion can take place at any time and on the same conditions. Individual contract negotiations will not be conducted. The earliest contract start date is 01.10.2026. Based on this, the contract duration is a maximum of 24 months. The contract ends on 30.09.2028, regardless of the contract start date. If, during the contract period, AOK Hessen carries out a tender for exclusive contracts in the form of an Open Procedure for the active substances, the contracts concluded within the framework of this publication will be terminated in accordance with the contractual provisions.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Apothekendienstleistungen für Kliniken
DRV Bund EinkaufsmanagementGermanyPharmaceutical productsDeadline in 32 daysPublished on Nov 12, 2026
Germany – Pharmaceutical products – 1/DLII6/VM131 - RV div. Arzneimittel
Bundesamt für Infrastruktur, Umweltschutz und Dienstleistungen der BundeswehrGermanyPharmaceutical productsDeadline in 10 daysPublished on Nov 12, 2026
Germany – Surgical instruments – 6003-1 Sinsheim, GRN-Klinik, Neubau Funktionstrakt, Chirurgiegeräte
Eigenbetrieb Bau, Vermögen und Informationstechnik Rhein-Neckar-KreisGermanySurgical instrumentsDeadline in 31 daysPublished on Nov 12, 2026
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV95
GWQ ServicePlus AGGermanyPharmaceutical productsDeadline in 270 daysPublished on Nov 12, 2026